NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, announced on Wednesday that it has named Joseph Hooker as its interim chief executive officer and president.

Hooker has held the position of independent consultant and advised on an ad hoc basis for leading management consultancies and various pharmaceutical companies relating to clinical trials, CROs and program management. He has held the position of senior director of clinical operations/program leader Rare Disease, Oncology at X4 Pharmaceuticals, Inc., director, Program Leadership at Biogen, senior director, Clinical Operations at Pierian Bioscience, chief operating officer of MedAvante-ProPhase and head, Clinical Operations for Sandoz Biopharmaceuticals. He started his pharmaceutical career as senior clinical trial manager and project leader at DuPont-Merck Pharmaceuticals, and also served at various times in clinical trial management roles at Shire Pharmaceuticals, Cephalon Pharmaceuticals, Quintiles and Novo Nordisk.

Andrew I Koven, chairman of the NeuroBo board of directors, said, 'We are at an important stage in the evolution of NeuroBo, so we are pleased to have Joe serve as our president and CEO on an interim basis as we conduct a search for our next CEO. Joe's experience and demonstrated leadership are an ideal fit for NeuroBo as we move our newly acquired assets, DA-1241 and DA-1726, into the next stages of clinical development and address the other strategies instrumental to NeuroBo's success. We expect to benefit from Joe's combination of clinical, business development and executive expertise, and his diverse experience working with a number of emerging and large biopharmaceutical companies.'